Department of Dermatology, University Hospital Doctor Peset of Valencia, Valencia, Spain.
Department of Dermatology, University Hospital Doctor Peset of Valencia, Valencia, Spain.
Actas Dermosifiliogr. 2024 Jul-Aug;115(7):722-726. doi: 10.1016/j.ad.2023.08.019. Epub 2024 Mar 29.
Tildrakizumab is an IL-23-inhibitor that has been approved to treat plaque psoriasis. However, few reports have become available on its efficacy profile in the real-world. Our objective was to study the mid-term efficacy of tildrakizumab in patients with moderate-to-severe psoriasis in the Spanish routine clinical practice setting. This was a retrospective multicenter study that included a total of 91 psoriatic patients on tildrakizumab. The mean Psoriasis Area and Severity Index (PASI) was 9.09 (SD, 5.30). The overall tildrakizumab survival rate was 93.47% for a mean treatment exposure of 30.18 weeks (SD, 16.57). No drug discontinuation was associated with drug tolerability, or adverse reactions. Absolute PASI ≤3 was reached by 91.3% and 96.5% of the patients on weeks 28 and 52, respectively. Response was not impacted by weight, age (>65), metabolic syndrome, presence of arthritis, or previous number of biological therapies used. Based on our own experience tildrakizumab is an effective strategy to treat plaque psoriasis and difficult-to-treat-areas.
替西单抗是一种白细胞介素 23 抑制剂，已被批准用于治疗斑块状银屑病。然而，关于其在真实世界中的疗效概况的报道很少。我们的目的是研究替西单抗在西班牙常规临床实践环境中治疗中重度银屑病患者的中期疗效。这是一项回顾性多中心研究，共纳入了 91 名接受替西单抗治疗的银屑病患者。平均银屑病面积和严重程度指数（PASI）为 9.09（SD，5.30）。在平均治疗暴露 30.18 周（SD，16.57）后，替西单抗的总生存率为 93.47%。没有因药物耐受性或不良反应而停药。在第 28 周和第 52 周，分别有 91.3%和 96.5%的患者达到 PASI 绝对值≤3。体重、年龄（>65 岁）、代谢综合征、关节炎存在或之前使用的生物治疗数量均不影响应答。根据我们的经验，替西单抗是治疗斑块状银屑病和难治性区域的有效策略。
